Teva/Bio-Technology General Corp.'s human growth hormone Tev-Tropin will be introduced "at the earliest opportunity" following U.S. appellate court decision to vacate June 2002 preliminary injunction against U.S. marketing of the product, BTG says. The injunction was requested by Novo. The company's process patent case arose out of previous process patent litigation between BTG and Genentech, which was resolved when BTG received FDA approval to change its manufacturing process (1"The Pink Sheet" May 8, 2000, p. 22). Novo claimed BTG's manufacturing change violated Novo patents. Teva holds marketing rights to Tev-Tropin and has ultimate decision on a launch date, BTG says...
You may also be interested in...
Teva's smooth performance in the multiple sclerosis market is shoring up the company in a difficult environment for biopharmaceutical stocks.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.